Skip to main content
Premium Trial:

Request an Annual Quote

Structural Biologists Absorb Light Sources


Structural biologists have quietly encroached on the turf of material sciences. According to Ari Patrinos, associate director for biological and environmental research at the US Department of Energy, protein structure researchers have usurped more and more time on synchrotons in the past decade. Life sciences activity at synchrotron light sources ballooned from less than five percent of total experiments in 1990 to more than 40 percent in 2000. To be specific, of 6,000 experiments conducted at the four DOE-funded synchrotrons — the Advanced Light Source in Berkeley, the Advanced Photon Source in Argonne, the National Synchrotron Light Source in Brookhaven, and the Stanford Synchrotron Radiation Laboratory — 2,400 were in the life science arena.

Material sciences experiments, which in 1990 accounted for more than 50 percent of synchrotron activity, represented less than 30 percent of work done at those sites in 2000.

To satisfy increasing demand from the bio sector, Patrinos says 15 more “structural biology stations for crystallography” are expected to open by 2003, and another four are under consideration.

Patrinos notes that between October and December 2000, scientists deposited more than 750 structures in the Protein Data Bank. If just half of all crystallography stations were dedicated to the task, 30,000 protein structures could be generated per year, he estimates.

— Adrienne Burke


The Scan

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Whale Decline Analysis

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.